Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic ImplicationRiccardo G. Borroni, Rita De Sanctis, Mariangela Gaudio et al.|The Oncologist|2024Cited by 9